Reference number : 172-2023-2024-Q4-1015631, amendment number : , agreement type : G, recipient legal name : Ottawa Hospital Research Institute, recipient country : CA, recipient province : ON, recipient city : Ottawa|Ottawa, recipient postal code : K1Y 4E9, program name english : Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives, program name french : Programme de collaboration en science, en technologie et en innovation - Initiatives de collaboration en R-D, program purpose english : Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas., program purpose french : Collaborer à des programmes multipartites de recherche-développement dans le but de profiter de la synergie entre la recherche transformatrice à haut risque et à haut rendement et le potentiel de découvertes scientifiques et de percées technologiques révolutionnaires dans des secteurs d’intervention prioritaires., agreement title english : Development and application of qualified testing in support of Clinical CAR-T Products, agreement title french : Développement et application d’essais qualifiés à l’appui des produits cliniques CAR-T, agreement number : 1015631, agreement value : 691045.0, agreement start date : 2024-02-20, agreement end date : 2026-03-10, description english : With the collaboration of research hospitals across Canada, OHRI established a multi-site cellular immunotherapy pipeline. In the Project, OHRI will build on their success in establishing clinical grade manufacturing for both lentivirus and cell products, and the execution of the first clinical trial using a made-in-Canada CD19 CAR T-cell therapy. The project includes building capacity in point-of-care (POC) manufacturing to support the clinical rollout of novel CAR T-cell products and other personalized cell therapy products. The project will both increase manufacturing capacity and allow for GMP process development. This increased capacity will be used to for academically motivated clinical trials to be started by late 2024. These trials will be completed over the next five years for the benefit of cancer patients from across Canada, description french : Développement et application d’essais qualifiés à l’appui des produits cliniques CAR-T, expected results english : In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems., expected results french : À court terme, les résultats prévus seront des collaborations renforcées entre l'industrie, le milieu universitaire et le gouvernement pour soutenir l'excellence en recherche. À moyen terme, les résultats attendus seront le développement de nouvelles technologies potentiellement perturbatrices avec des collaborateurs. À long terme, trouver des solutions collaboratives aux défis des politiques publiques et créer des systèmes d'innovation plus solides., additional information english : nan, additional information french : nan, owner organization : nrc-cnrc, owner organization title : National Research Council Canada | Conseil national de recherches Canada